TISSIUM

@tissiumtech

MedTech company dedicated to the development of biomorphic programmable polymers for tissue reconstruction.

Paris, France
Vrijeme pridruživanja: srpanj 2013.

Tweetovi

Blokirali ste korisnika/cu @tissiumtech

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @tissiumtech

  1. 21. sij
    Poništi
  2. 20. sij

    Thrilled to be named a company - Heureux de faire partie de la

    Poništi
  3. 14. sij

    Find out how TISSIUM innovates with one of the 10 greatest medtech advances of the 2010s:

    Poništi
  4. 2. pro 2019.

    TISSIUM’s Chief Innovation Officer Maria Pereira will present at in New York City this Wednesday, December 4th. Hosted by the Crohn's & Colitis Foundation, the conference highlights new ways to meet the needs of patients. Learn more at:

    Poništi
  5. proslijedio/la je Tweet

    Wound treatment developer has raised €38.75m (US$42.8m) Series B funding to support the company’s expansion globally, particularly in the fields of nerve repair, cardiovascular and gastroenterology treatments

    Poništi
  6. proslijedio/la je Tweet
    20. stu 2019.

    Tissium is also setting up a manufacturing facility in Lille, France. The company thinks the completion of the facility will aid its efforts to streamline product development:

    Poništi
  7. 26. stu 2019.

    La stratégie de est de créer un vaste portefeuille de produits. Découvrez les moyens innovateurs que nous employons pour développer notre plateforme technologique:

    Poništi
  8. proslijedio/la je Tweet
    20. stu 2019.

    Tissium closes €39 million funding round, Jay Watkins to join board

    Poništi
  9. 25. stu 2019.

    Interested in learning more about the different clinical applications of TISSIUM polymers? Here's your exclusive look at how we develop to address unmet needs:

    Poništi
  10. proslijedio/la je Tweet
    25. stu 2019.

    . develops that can act as surgical glue or be 3D-printed as implants. The company has raised a €38.8M Series B round to fund the development of polymers that can be used to repair blood vessels and nerves.

    Poništi
  11. 25. stu 2019.
    Poništi
  12. proslijedio/la je Tweet
    20. stu 2019.
    Poništi
  13. 22. stu 2019.

    TISSIUM a ​levé 39 millions d'euros pour étendre la plateforme des polymères dans divers domaines thérapeutiques. Notre CEO Christophe Bancel explique sur BFM Business:

    Poništi
  14. 21. stu 2019.

    TISSIUM polymers are biocompatible and can be absorbed by the body. Our CEO Christophe Bancel explains:

    Poništi
  15. 20. stu 2019.
    Poništi
  16. 18. ruj 2019.

    Next week, we will exhibit at the 33rd Annual Meeting of the European Society of Vascular Surgery in Hamburg, Germany. Visit our booth to learn more about TISSIUM's biomorphic programmable polymers and innovations in vascular surgery.

    Poništi
  17. 12. ruj 2019.

    Au cas où vous l’auriez manqué, retrouvez le podcast « Les trésors du Biomimétisme » de La France bouge sur Europe 1 en cliquant sur le lien ci-dessous !

    Poništi
  18. 10. ruj 2019.

    “Comment TISSIUM invente t’elle le monde de demain ?" Pour en savoir plus, suivez en direct l’édition de demain de « La France bouge » sur Europe 1 dès 13:10»

    Poništi
  19. 2. ruj 2019.

    TISSIUM’s multi-tasking CEO on how planning for the best — while preparing for the worst — can be the difference between a startup’s success or failure: From the May 2019 issue of

    Poništi
  20. 30. kol 2019.

    “We see ourselves as an innovation engine.” See how our CEO Christophe Bancel and the team at TISSIUM are driving a new era in tissue reconstruction with our scalable, platform-based polymer . From the May 2019 issue of

    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·